STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex...
Read More Details
Finally We wish PressBee provided you with enough information of ( EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN )
Also on site :
- Reform MP James McMurdock suspends himself from party over ‘business propriety during pandemic’
- Disturbed’s David Draiman Met with Some Boos at Final Black Sabbath Concert
- Trump wants more skilled tradespeople. His Labor Department is trying to cut off a pipeline of workers